Logo

kidney cancer

Allarity Therapeutics Seeks FDA Premarket Approval for Prediction Tool as CDx for Dovitinib

The DRP would be used to identify kidney cancer patients likely to benefit from dovitinib, a repurposed TKI for which Allarity plans to file an NDA this year.

Microbiome-Based Cancer Dx Emerges From Cancer Genome Atlas Reanalysis

Researchers re-examined whole-genome and whole-transcriptome sequencing TCGA studies from 33 cancer types and found unique microbial signatures.

Swedish Diagnostics Firm Elypta Raises €6.1M

The Stockholm-based company said it will use the funds to develop its metabolism-based liquid biopsy platform.

Metabolism-Based Liquid Biopsy Tool Being Developed by Elypta for Recurrent Renal Cell Cancer
Premium

Elypta anticipates launching a test to conduct surveillance for recurrence of renal cell carcinoma in patients that have undergone surgery.

Natera Partners With Fox Chase to Evaluate ctDNA Cancer Assay

The Signatera research-use-only assay monitors cancer treatment and assesses minimal residual disease, and is customized for individual patients.